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HIV-infected patients are at increased risk for both vaccine-pre-
ventable diseases and their complications, with mortality rates 
higher than in non-HIV-infected individuals. Consequently, 
international guidelines generally recommend inactivated 
vaccines in HIV-patients, even if HIV-related immunode-
ficiency may impair efficacy; live vaccines are usually not 
recommended in these patients because of safety concerns. 
The aim of this short article is to review current knowledge 
about both efficacy and safety of vaccines in HIV-infected 
individuals.
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Summary
Introduction
Human Immunodeficiency Virus (HIV) infection is a 
leading cause of morbidity and mortality [1]. If untreat-
ed, HIV leads to a progressive impairment of the cel-
lular immunity, thus increasing the risk of opportunistic 
infections and malignancies [2, 3]. 
Parameters most commonly used to monitor the advance-
ment of the disease include the plasmatic HIV viral load 
(HIV-RNA) and the serum CD4-T cell count [4]. Indeed, 
a detectable plasmatic HIV-RNA reflects an active viral 
replication, while a reduced CD4-T cell count suggests an 
impoverishment of the immune response against infections 
and cancers. On the other hand, an undetectable plasmatic 
HIV-RNA and an increased serum CD4-T cell count are 
both markers of favorable response to antiretroviral therapy 
(ART), the latter being also associated with a dramatic re-
duction in the risk of opportunistic infections [5, 6]. How-
ever, despite immunovirological control with ART, HIV 
infection remains associated with residual perturbations 
of the immune cellular response, including both T- and 
B-cells [7]. If we accept the idea that even in immunovi-
rological controlled HIV-infected patients the immune sys-
tem does not work normally, it is conceivable that immune 
response to vaccines may remain sub-optimal, as well. 
Attempting to deal with this important matter, in this 
paper we review current literature about efficacy of vac-
cinations in HIV-infected adults, as well as safety con-
cerns regarding the administration of live vaccines. 
Impact of vaccine-preventable diseases 
in HIV patients
HIV-infected patients are at increased risk for the devel-
opment of both vaccine-preventable diseases and their 
complications, with higher mortality rates than in non-
HIV-infected individuals.
Streptococcus pneumoniae pneumonia is a leading 
cause of death worldwide, although its survival has dra-
matically improved in the last century due to improved 
nutrition and life conditions together with public health 
measures and the advent of the antibiotic era [8]. As re-
gards the impact of HIV infection on the outcome of this 
disease, mortality of S. pneumoniae pneumonia and/or 
bacteremia has been reported to be higher in HIV-infect-
ed patients than in HIV non-infected subjects, even after 
the introduction of ART [9, 10].
An association between increased mortality and HIV in-
fection has also been reported for influenza in patients 
with severe immunodeficiency, with high influenza-
attributable risk of acute cardiopulmonary event  [11]. 
For these reasons both anti-pneumococcal and anti-
influenza vaccines are recommended for HIV-infected 
individuals, with preference, in the case of influenza, 
for inactivated vaccines  [12-14]. An inactivated influ-
enza vaccine should thus be administered annually to 
all HIV-infected individuals [12]. Of note, avoiding the 
development of influenza through vaccination is also an 
indirect way to prevent bacterial pneumonia which can 
occur as a complication of the viral disease [12]. 
The considerable impact of some other vaccine-prevent-
able diseases in HIV-infected patients is not only related 
to their acute-phase mortality, but it also derives from 
the high prevalence of these diseases in the HIV popula-
tion, with effects on long-term morbidity and mortality. 
For example, international guidelines recommend vacci-
nation of HIV-infected patients against hepatitis A virus 
(HAV), hepatitis B virus (HBV) and human papilloma-
virus (HPV), even if complete and reliable data regard-
ing efficacy of these vaccines in HIV-infected patients 
are not available [13].
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It has been demonstrated that HIV-infected patients are 
at higher risk for HBV infection in comparison with non-
HIV-infected subjects, since HBV shares the same routes 
of transmission of HIV. In addition, HBV infection signif-
icantly increases liver-related mortality in HIV-1-infected 
patient  [15], especially for those with low CD4-T nadir 
count [15, 16]. Moreover, due to some shared risk factors 
(i.e., intravenous drug use and being a man who have sex 
with man), also vaccination against HAV should be con-
sidered in HIV-infected patients [17, 18]. 
Similarly to hepatotropic viruses, the prevalence of 
HPV-related diseases in HIV-infected patients is higher 
than in non-HIV-infected individuals. Therefore, HIV 
women are at higher risk for developing cervical in-
traepithelial neoplasm and cervical cancer in compari-
son with the general population  [19-23]. Accordingly, 
HPV vaccine is strongly recommended for HIV-infected 
girls aged 9 through 26 years by Italian and ACIP guide-
lines, while only a moderate recommendation is provid-
ed by American guidelines, due to the lack of complete 
efficacy data in the HIV population [12-14].
Finally and obviously, HIV-infected individuals are at 
risk of preventable diseases such as tetanus, diphtheria 
and pertussis with no difference with respect to the gen-
eral population, and should therefore receive specific 
vaccinations. 
Detailed international schedules for different types of 
vaccinations in both HIV-infected and non-HIV-infect-
ed patients can be found at http://www.cdc.gov/vac-
cines/hcp/acip-recs/index.html [14]. 
Efficacy and immunogenicity of different 
vaccines in the HIV setting
The vaccine efficacy in preventing disease in HIV-in-
fected patients has been demonstrated for S. pneumoniae 
and influenza viruses associated diseases.
As regards S. pneumoniae, Rodriguez-Barradas et al 
compared 692 non-HIV-infected and 934 HIV-infected 
subjects in a randomized clinical trial, the 59% of whom 
were vaccinated with the 23-valent pneumococcal pol-
ysaccharide vaccine  [24]. The primary endpoint was 
time to the first pneumonia event, after controlling for 
HIV-specific variables. They found that the anti-pneu-
mococcal vaccination significantly reduced the risk of 
pneumonia (HR 0.65, 95% CI 0.42-1.00, p  =  0.05) in 
HIV-infected patients, while the impact of vaccination 
in non-HIV-infected was not significant [24]. 
A recent systematic review investigated the efficacy and 
the effectiveness of influenza vaccination in 1562 HIV-
patients  [25]. Data was retrieved from 3 randomized-
controlled trials (RCT) and 3 observational studies. The 
authors observed a pooled efficacy of 85% in prevent-
ing laboratory-confirmed influenza (95% CI 22-97%) 
among adult patients, while this effect was not con-
firmed in young children  [25]. In the 3 observational 
studies, a favorable effect of vaccination was reported 
only in one of them, with an effectiveness of 71% (95% 
CI 44-85%) in preventing laboratory-confirmed influ-
enza [15]. However, it should be noted that a high risk 
of bias was reported in all the 3 observational studies 
included [15].
For other vaccines, such as those against HBV, HAV, and 
HPV, immunogenicity has been used as a surrogate mark-
er for clinical effectiveness in several observational stud-
ies, while no randomized trials have still validated their 
efficacy and effectiveness in preventing disease [26]. 
Two studies compared rates of serological response to 
HBV vaccination in HIV-infected vs. non-HIV-infect-
ed individuals. In the first, Irungu et al. found that the 
nonresponse to HBV vaccine was higher in 310 HIV-
infected patients than in 293 non-HIV-infected subjects 
(35% vs 14%, p < 0.001) [27]. In the second study, Col-
lier et al. compared 16 HIV-infected and 68 non-HIV-
infected children and found that subjects who were HIV-
infected frequently lacked protective levels of anti-HBs 
titers after three doses of 20 µg of recombinant HBsAg in 
comparison to HIV-uninfected individuals (44% vs 9%, 
p = 0.002) [28].
About HAV, Neilsen et al. investigated 90 HIV-infect-
ed and 44 non-HIV-infected subjects, both receiving a 
2 dose vaccination course  [29]. The authors observed 
that among patients tested for seroconversion after two 
vaccination doses the HAV seroconversion rate was sig-
nificantly lower in HIV-positive patients in comparison 
with HIV-negative subjects (88.2%% vs 100%, respec-
tively, p  =  0.03) [29]. In addition, in the subgroup of 
HIV-infected patients, baseline CD4-T cell count was 
considerably higher in those who showed serological re-
sponse to HAV vaccination than in those who did not 
(mean baseline CD4-T cell count 540/µL vs 280/µL, re-
spectively, p = 0.033) [29]. On the other hand, Wallace 
and coworkers studied HAV seroconversion rates after 
vaccination among 90 HIV-infected and 90 non-HIV-
infected patients. In this exerience, antibody responses 
were sustained among the non-HIV-infected subjects 
(100%, 95%CI 95-100) and HIV-infected subjects with 
CD4-T cell count higher than 300/μL (100%, 95%CI 
87-100), but they decreased  among patients who had 
had CD4-T cell counts lower than 300 cells/mm3 at en-
rollment (87%, 95%CI, 66-97)  [30]. Finally, Tseng et 
al. reported an unfavorable association between HIV in-
fection and response to HAV vaccination independently 
from receiving either two or three doses of HAV vaccine 
(p = 0.01) [31].
With regard to HPV vaccination in adults, a phase 2 
open-label multicenter trial found the 3-dose quad-
rivalent HPV vaccine to be immunogenic in 99 young 
HIV-infected women aged 16-23 years. The observed 
seroconversion rates were as high as 100% for HPV-6, 
11, 16, and 18 among women on ART [32]. Moreover, 
Wilkin et al. found that the same vaccine was immu-
nogenic among 109 HIV-infected men ≥ 18 years, with 
seroconversion rates of 98% for HPV-6 (59/60), 99% for 
HPV- 11 (67/68), 100% for HPV-16 (62/62), and 95% 
(74/78) for HPV-18 (74/78) [33].
Finally, optimal revaccination strategies for patients 
with no serological response to vaccination schedules 
are still under debate. 
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Impact of vaccination on HIV-infection
Interestingly, some authors have highlighted responses 
to vaccination from an HIV standpoint, aiming at eluci-
dating any possible impact of different vaccines on the 
course of the HIV-related disease. 
For influenza vaccination, Durando et al. did not report 
any increase in both HIV replication and CD4-T cell 
count following influenza vaccination with two differ-
ent virus subunit vaccines at three time points, whereas 
Calmy et al. detected transient increases in HIV-RNA 
levels in 3 of 66 (4.5%) previously aviremic HIV pa-
tients who received two doses of an AS03-adjuvated flu 
pandemic vaccine [34]. Of note, these transient increases 
did not recur after boosting with a non-AS03-adjuvated 
influenza vaccine. Similarly, Onlamoon et al. observed 
detectable plasmatic HIV-RNA levels among 8/37 pre-
viously aviremic HIV-infected patients (22%) who re-
ceived a monovalent non-adjuvated influenza A H1N1 
2009 vaccine, even though a concomitant increase in 
lymphocytes activation was not observed [35]. 
Two clinical trials did not report any effect on plasmatic 
HIV-RNA and serum CD4-T cell count after HAV and 
HBV vaccination, respectively  [27, 29, 36]. Similarly, 
Levin et al. did not observe significant changes in CD4-
T cell counts in HIV-infected children receiving a live 
attenuated varicella vaccine, whereas an increase in 
CD4-T cell activation was observed by Stanley et al. fol-
lowing tetanus immunization, resulting in an enhanced 
CD4-T cells susceptibility to both HIV infection and 
replication [37, 38].
Finally, it is worth noting that no ART failure was ob-
served in the study of Calmy et al., which, as detailed 
above, reported an increase in HIV RNA levels follow-
ing vaccination [34]. However, this possibility remains 
of some concern, since HIV drug resistance muta-
tions can be selected in presence of low-level viremia 
[39, 40]. Whether or not this risk is also present during 
transient increases of HIV-RNA in the post-vaccination 
period deserves further investigations.
Safety of vaccination in HIV patients
When administering vaccines, as well as any other 
medication, the development of adverse events may oc-
cur. To this regard, inactivated vaccines are generally 
reported to be well tolerated in HIV patients, with the 
most frequent side effects being mild and transient lo-
cal reactions, including pain, redness, swelling, and 
mild systemic reaction, like headache, fever and general 
discomfort [24, 30, 36, 41-46]. Although Wallace et al. 
described a slightly higher rate of systemic adverse reac-
tions in HIV-infected individuals receiving HAV vac-
cination in comparison with both HIV infected subjects 
receiving placebo and non-HIV-infected subjects re-
ceiving HAV vaccination (37% vs 23% vs 21%, respec-
tively), no other differences in the incidence of vaccine-
related adverse events between HIV-infected and non-
HIV-infected subjects have been reported so far [30]. 
A particular safety concern regarding vaccines adminis-
tration in HIV patients is the possibility for a live vac-
cine itself to cause disease. In fact, live-attenuated vac-
cines might be harmful in patients with severe immuno-
deficiency. For this reason, international guidelines do 
not recommend measles vaccination in severely immu-
nosuppressed patients. Anecdotal reports confirm that 
measles vaccination is potentially dangerous in these 
patients. For example, an HIV-infected patient who re-
ceived measles vaccination developed deadly giant-cell 
pneumonitis one year after. Genomic sequence analysis 
revealed that the measles virus in lung tissue was similar 
to vaccine viruses [47]. In addition, in the pre-HAART 
era several case reports described the development 
of severe disease after varicella and BCG vaccines in 
HIV-infected adults  [48-50]. Whether or not live vac-
cines might be used in patients achieving good immu-
novirological response is a matter of concern. Several 
recent investigations reported that live vaccines against 
varicella, zoster and yellow fever were safe in HIV-
infected children and adults  [37,  46,  51]. However, it 
should be noted that these studies largely involved those 
HIV patients without a severe degree of immunodefi-
ciency  [37,  46,  51]. Nevertheless, live-attenuated vac-
cines remains contraindicated in HIV-infected patients 
with low CD4-T cell count (i.e. < 200/µL) [14]. 
Conclusions
Despite the lack of a complete and reliable efficacy 
data, avoiding the development of preventable diseases 
through vaccination might be critical in HIV-infected 
individuals, especially because the immunovirological 
competence in these patients might be questionable even 
after viral response and apparently complete immuno-
logical recovery. Indeed, these patients should follow 
tailored vaccination schedules, to prevent diseases that 
carry a high burden in terms of morbidity and mortal-
ity in the HIV population, such as S. pneumoniae pneu-
moniae, influenza, HBV and HPV infection. Vaccines 
should be administered without waiting for full CD4-
T cell count recovery, although immunodeficiency is a 
possible risk factor for lack of response to vaccination. 
Finally, inactivated or subunits vaccines should be pre-
ferred, since further studies are needed to adequately 
investigate the safety of live vaccines in HIV-infected 
patients.
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